- Home
- NMT vs BMEA Comparison
NMT vs BMEA Comparison
Compare NMT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- BMEA
- Stock Information
- Founded
- NMT 1993
- BMEA 2017
- Country
- NMT United States
- BMEA United States
- Employees
- NMT N/A
- BMEA N/A
- Industry
- NMT Finance/Investors Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- NMT Finance
- BMEA Health Care
- Exchange
- NMT Nasdaq
- BMEA Nasdaq
- Market Cap
- NMT 106.2M
- BMEA 103.5M
- IPO Year
- NMT N/A
- BMEA 2021
- Fundamental
- Price
- NMT $11.19
- BMEA $1.83
- Analyst Decision
- NMT
- BMEA Strong Buy
- Analyst Count
- NMT 0
- BMEA 10
- Target Price
- NMT N/A
- BMEA $17.70
- AVG Volume (30 Days)
- NMT 19.1K
- BMEA 683.1K
- Earning Date
- NMT 01-01-0001
- BMEA 08-05-2025
- Dividend Yield
- NMT 3.21%
- BMEA N/A
- EPS Growth
- NMT N/A
- BMEA N/A
- EPS
- NMT N/A
- BMEA N/A
- Revenue
- NMT N/A
- BMEA N/A
- Revenue This Year
- NMT N/A
- BMEA N/A
- Revenue Next Year
- NMT N/A
- BMEA N/A
- P/E Ratio
- NMT N/A
- BMEA N/A
- Revenue Growth
- NMT N/A
- BMEA N/A
- 52 Week Low
- NMT $9.05
- BMEA $1.29
- 52 Week High
- NMT $10.93
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- NMT 37.56
- BMEA 56.62
- Support Level
- NMT $11.14
- BMEA $1.51
- Resistance Level
- NMT $11.32
- BMEA $1.86
- Average True Range (ATR)
- NMT 0.11
- BMEA 0.10
- MACD
- NMT -0.00
- BMEA 0.03
- Stochastic Oscillator
- NMT 15.15
- BMEA 91.67
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.